Back

Efficacy and safety of the ICD in patients with catecholaminergic polymorphic ventricular tachycardia

27 August 2022 (12:10 - 12:20)
Organised by:
Congress Presentation Part of: Emerging role of genetic testing for ventricular arrhythmia management Device Treatment ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Associate Professor Andrea Mazzanti

University of Pavia, Pavia (Italy)

4 More presentations in this session

Presentation thumbnail
SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome
Professor V. Probst (Nantes, FR)
Abstract Slides Video
Presentation thumbnail
Natural History of Patients with Typical and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia
Doctor A. Trancuccio (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
Calmodulinopathy is a common cause of critical cardiac phenotypes in fetus and infancy
Doctor M. Fukuyama (Otsu, JP)
Abstract Slides Video
Presentation thumbnail
Longitudinal validation of the phospholamban (PLN) p.Arg14del risk model
Miss M. Van Der Heide (Amsterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Emerging role of genetic testing for ventricular arrhythmia management

The Event

Event poster

ESC Congress 2022

27 August 2022 12:10 CET
You may be interested in
thumbnail
Congress Presentation
Risk stratification of sudden cardiac death in catecholaminergic polymorphic ventricular tachycardia
thumbnail
Congress Presentation
Acute in vivo antiarrhythmic effects of cGMP-modifying drugs in the R2474S mouse model of catecholiminergic polymorphic ventricular tachycardia.
thumbnail
Congress Session
Debate on primary prevention in ICD therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources